Search

Your search keyword '"van der Boon, Robert M.A."' showing total 35 results
Start Over Author "van der Boon, Robert M.A."
35 results on '"van der Boon, Robert M.A."'

1. Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study

Author

Malgie, Jishnu, primary, Wilde, Mariëlle I., additional, Clephas, Pascal R.D., additional, Emans, Mireille E., additional, Koudstaal, Stefan, additional, Schaap, Jeroen, additional, Mosterd, Arend, additional, van Ramshorst, Jan, additional, Wardeh, Alexander J., additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, Wierda, Eric, additional, Borleffs, C. Jan Willem, additional, Saraber, Colette, additional, Beeres, Saskia L.M.A., additional, van Kimmenade, Roland, additional, Jansen Klomp, Wouter, additional, Denham, Robert, additional, da Fonseca, Carlos A., additional, Klip, IJsbrand T., additional, Manintveld, Olivier C., additional, van der Boon, Robert M.A., additional, van Ofwegen, Clara E.E., additional, Yilmaz, Ayten, additional, Pisters, Ron, additional, Linssen, Gerard C.M., additional, Faber, Nikola, additional, van Heerebeek, Loek, additional, van de Swaluw, Julio E.C., additional, Bouhuijzen, Lex J., additional, Post, Marco C., additional, Kuijper, Aaf F.M., additional, Wu, Ka wai, additional, van Beek, Eugène A., additional, Hesselink, Tim, additional, Kleijn, Lennaert, additional, Kurvers, Maurice J.M., additional, Tio, René A., additional, Langerveld, Jorina, additional, van Dalen, Bas M., additional, van Eck, J.W. Martijn, additional, Handoko, M. Louis, additional, Hermans, Walter R.M., additional, Koornstra‐Wortel, Hetty J.J., additional, Szymanski, Mariusz K., additional, Rooker, Dennis, additional, Tandjung, Kenneth, additional, Eijsbouts, Sabine C.M., additional, Asselbergs, Folkert W., additional, van der Meer, Peter, additional, Brunner‐La Rocca, Hans‐Peter, additional, de Boer, Rudolf A., additional, and Brugts, Jasper J., additional

Published
2024
Full Text
View/download PDF

2. The different risk of new-onset, chronic, worsening, and advanced heart failure:A systematic review and meta-regression analysis

Author

Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., Brugts, Jasper J., Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., and Brugts, Jasper J.

Abstract

Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all-cause mortality and HF hospitalizations associated with new-onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF. Methods and results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30-day and 1-year all-cause mortality, as well as 1-year HF hospitalization. Studies were pooled using random effects meta-analysis, and mixed-effects meta-regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30-day mortality rates did not reveal a significant distinction between hospital-admitted patients, with rates of 10.13% for new-onset HF and 8.11% for WHF (p = 0.10). However, the 1-year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new-onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend. Conclusions: Our meta-analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF.

Published
2024

3. The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis.

Author

Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., and Brugts, Jasper J.

Subjects
HEART failure, PROGNOSIS, MORTALITY, DEATH rate, SCIENTIFIC observation, CONFIDENCE intervals
Abstract

Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all‐cause mortality and HF hospitalizations associated with new‐onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF. Methods and results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30‐day and 1‐year all‐cause mortality, as well as 1‐year HF hospitalization. Studies were pooled using random effects meta‐analysis, and mixed‐effects meta‐regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30‐day mortality rates did not reveal a significant distinction between hospital‐admitted patients, with rates of 10.13% for new‐onset HF and 8.11% for WHF (p = 0.10). However, the 1‐year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new‐onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend. Conclusions: Our meta‐analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Telemonitoring for heart failure:a meta-analysis

Author

Scholte, Niels T.B., Gürgöze, Muhammed T., Aydin, Dilan, Theuns, Dominic A.M.J., Manintveld, Olivier C., Ronner, Eelko, Boersma, Eric, de Boer, Rudolf A., van der Boon, Robert M.A., Brugts, Jasper J., Scholte, Niels T.B., Gürgöze, Muhammed T., Aydin, Dilan, Theuns, Dominic A.M.J., Manintveld, Olivier C., Ronner, Eelko, Boersma, Eric, de Boer, Rudolf A., van der Boon, Robert M.A., and Brugts, Jasper J.

Abstract

AIMS: Telemonitoring modalities in heart failure (HF) have been proposed as being essential for future organization and transition of HF care, however, efficacy has not been proven. A comprehensive meta-analysis of studies on home telemonitoring systems (hTMS) in HF and the effect on clinical outcomes are provided. METHODS AND RESULTS: A systematic literature search was performed in four bibliographic databases, including randomized trials and observational studies that were published during January 1996-July 2022. A random-effects meta-analysis was carried out comparing hTMS with standard of care. All-cause mortality, first HF hospitalization, and total HF hospitalizations were evaluated as study endpoints. Sixty-five non-invasive hTMS studies and 27 invasive hTMS studies enrolled 36 549 HF patients, with a mean follow-up of 11.5 months. In patients using hTMS compared with standard of care, a significant 16% reduction in all-cause mortality was observed [pooled odds ratio (OR): 0.84, 95% confidence interval (CI): 0.77-0.93, I2: 24%], as well as a significant 19% reduction in first HF hospitalization (OR: 0.81, 95% CI 0.74-0.88, I2: 22%) and a 15% reduction in total HF hospitalizations (pooled incidence rate ratio: 0.85, 95% CI 0.76-0.96, I2: 70%). CONCLUSION: These results are an advocacy for the use of hTMS in HF patients to reduce all-cause mortality and HF-related hospitalizations. Still, the methods of hTMS remain diverse, so future research should strive to standardize modes of effective hTMS.

Published
2023

6. Regional management of worsening heart failure:rationale and design of the CHAIN-HF registry

Author

Shakoor, Abdul, Emans, Mireille E., van Gent, Marco W.F., Hendrix, Anneke, Faber, Nikola, Springeling, Tirza S., de Vette, Liesbeth C., Manintveld, Olivier C., Denham, Robert N., van de Meerendonk, Chajja, van der Boon, Robert M.A., Brugts, Jasper J., Shakoor, Abdul, Emans, Mireille E., van Gent, Marco W.F., Hendrix, Anneke, Faber, Nikola, Springeling, Tirza S., de Vette, Liesbeth C., Manintveld, Olivier C., Denham, Robert N., van de Meerendonk, Chajja, van der Boon, Robert M.A., and Brugts, Jasper J.

Abstract

Aims: Heart failure (HF) is a progressive disease in which periods of clinical stability are interrupted by episodes of clinical deterioration known as worsening heart failure (WHF). Patients who develop WHF are at high risk of subsequent death, rehospitalization, and excessive healthcare costs. As such, WHF could be seen as a separate disease stage and precursor of advanced HF. Whether WHF has a substantial health, societal, and economic impact evidence regarding its multifactorial nature and the specific barriers in treatment, including advanced HF therapies, remains scarce. The CHAIN-HF registry aims to describe the incidence, characteristics, current treatment, and outcomes of WHF. Additionally, it will promote structured regional collaboration and educate on increasing awareness for WHF and describe the implementation of guideline directed medical therapy and utilization of advanced HF therapies in a collaborative network. Methods and results: The CHAIN-HF registry is a prospective, observational, and multicentre study from the collaborating hospitals (Rijnmond HF Network) in the Rotterdam area. Unselected and consecutive patients (irrespective of ejection fraction) with a WHF event will be included. Comprehensive data including demographics, co-morbidities, treatment, and in-hospital and post-discharge outcomes will be collected. Notably, data on socio-economic status, treatment decisions, and referral for advanced HF therapies will be included. Conclusions: CHAIN-HF will be the first prospective, dedicated WHF registry in a collaborative network of hospitals that will provide robust real-world evidence on the incidence, characteristics, and outcomes of WHF. Moreover, it will provide information on of the value of regional collaboration to improve awareness and outcomes of WHF.

Published
2023

7. Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry.

Author

Shakoor, Abdul, Emans, Mireille E., van Gent, Marco W.F., Hendrix, Anneke, Faber, Nikola, Springeling, Tirza S., de Vette, Liesbeth C., Manintveld, Olivier C., Denham, Robert N., van de Meerendonk, Chajja, van der Boon, Robert M.A., and Brugts, Jasper J.

Subjects
DESIGN failures, HEART failure, CLINICAL deterioration, VENTRICULAR ejection fraction, DISEASE progression, SOCIOECONOMIC status
Abstract

Aims: Heart failure (HF) is a progressive disease in which periods of clinical stability are interrupted by episodes of clinical deterioration known as worsening heart failure (WHF). Patients who develop WHF are at high risk of subsequent death, rehospitalization, and excessive healthcare costs. As such, WHF could be seen as a separate disease stage and precursor of advanced HF. Whether WHF has a substantial health, societal, and economic impact evidence regarding its multifactorial nature and the specific barriers in treatment, including advanced HF therapies, remains scarce. The CHAIN‐HF registry aims to describe the incidence, characteristics, current treatment, and outcomes of WHF. Additionally, it will promote structured regional collaboration and educate on increasing awareness for WHF and describe the implementation of guideline directed medical therapy and utilization of advanced HF therapies in a collaborative network. Methods and results: The CHAIN‐HF registry is a prospective, observational, and multicentre study from the collaborating hospitals (Rijnmond HF Network) in the Rotterdam area. Unselected and consecutive patients (irrespective of ejection fraction) with a WHF event will be included. Comprehensive data including demographics, co‐morbidities, treatment, and in‐hospital and post‐discharge outcomes will be collected. Notably, data on socio‐economic status, treatment decisions, and referral for advanced HF therapies will be included. Conclusions: CHAIN‐HF will be the first prospective, dedicated WHF registry in a collaborative network of hospitals that will provide robust real‐world evidence on the incidence, characteristics, and outcomes of WHF. Moreover, it will provide information on of the value of regional collaboration to improve awareness and outcomes of WHF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Incidence, Predictors, and Implications of Access Site Complications With Transfemoral Transcatheter Aortic Valve Implantation

Author

Van Mieghem, Nicolas M., Tchetche, Didier, Chieffo, Alaide, Dumonteil, Nicolas, Messika-Zeitoun, David, van der Boon, Robert M.A., Vahdat, Olivier, Buchanan, Gill L., Marcheix, Bertrand, Himbert, Dominique, Serruys, Patrick W., Fajadet, Jean, Colombo, Antonio, Carrié, Didier, Vahanian, Alec, and de Jaegere, Peter P.T.

Published
2012
Full Text
View/download PDF

12. Impact of Mixed Aortic Valve Stenosis on VARC-2 Outcomes and Postprocedural Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Implantation: Results From the International Multicentric Study PRAGMATIC (Pooled Rotterdam–Milan–Toulouse in Collaboration)

Author

Chieffo, Alaide, Van Mieghem, Nicolas M., Tchetche, Didier, Dumonteil, Nicolas, Giustino, Gennaro, Van der Boon, Robert M.A., Pierri, Adele, Marcheix, Bertrand, Misuraca, Leonardo, Serruys, Patrick W., Millischer, Damien, Carrié, Didier, de Jaegere, Peter P.T., and Colombo, Antonio

Published
2015
Full Text
View/download PDF

13. Safety of Endomyocardial Biopsy in New-Onset Acute Heart Failure Requiring Veno-Arterial Extracorporeal Membrane Oxygenation

Author

van der Boon, Robert M.A., primary, den Dekker, Wijnand K., additional, Meuwese, Christiaan L., additional, Lorusso, Roberto, additional, von der Thüsen, Jan H., additional, Constantinescu, Alina C., additional, Manintveld, Olivier C., additional, Delnoij, Thijs S.R., additional, van der Heijden, Joris. J., additional, van Mieghem, Nicolas M.D.A., additional, and den Uil, Corstiaan A., additional

Published
2021
Full Text
View/download PDF

15. Impact of preoperative chronic kidney disease on short- and long-term outcomes after transcatheter aortic valve implantation: A Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy

Author

Dumonteil, Nicolas, van der Boon, Robert M.A., Tchetche, Didier, Chieffo, Alaide, Van Mieghem, Nicolas M., Marcheix, Bertrand, Buchanan, Gill L., Vahdat, Olivier, Serruys, Patrick W., Fajadet, Jean, Colombo, Antonio, de Jaegere, Peter P.T., and Carrié, Didier

Published
2013
Full Text
View/download PDF

17. Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: Insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative

Author

Tchetche, Didier, Van der Boon, Robert M.A., Dumonteil, Nicolas, Chieffo, Alaide, Van Mieghem, Nicolas M., Farah, Bruno, Buchanan, Gill L., Saady, Redouane, Marcheix, Bertrand, Serruys, Patrick W., Colombo, Antonio, Carrie, Didier, De Jaegere, Peter P.T., and Fajadet, Jean

Published
2012
Full Text
View/download PDF

19. Reply

Author

van der Boon, Robert M.A., primary, van Domburg, Ron T., additional, and de Jaegere, Peter P.T., additional

Published
2016
Full Text
View/download PDF

20. Current decision making and short-term outcome in patients with degenerative aortic stenosis: the Pooled-RotterdAm-Milano-Toulouse In Collaboration Aortic Stenosis survey

Author

Van Mieghem, Nicolas M., primary, Dumonteil, Nicolas, additional, Chieffo, Alaide, additional, Roux, Yann, additional, van der Boon, Robert M.A, additional, Giustino, Gennaro, additional, Hartman, Eline, additional, Aga, Yaar, additional, de Jong, Louis, additional, Abi Ghanem, Moussa, additional, Marcheix, Bertrand, additional, Cavazza, Caterina, additional, Carrié, Didier, additional, Colombo, Antonio, additional, Kappetein, Arie-Pieter, additional, de Jaegere, Peter P.T., additional, and Tchetche, Didier, additional

Published
2016
Full Text
View/download PDF

22. Transcatheter Aortic Valve Implantation With the Edwards SAPIEN Versus the Medtronic CoreValve Revalving System Devices A Multicenter Collaborative Study: The PRAGMATIC Plus Initiative (Pooled-RotterdAm-Milano-Toulouse In Collaboration)

Author

Chieffo, Alaide, Buchanan, Gill Louise, Van Mieghem, Nicolas M., Tchetche, Didier, Dumonteil, Nicolas, Latib, Azeem, van der Boon, Robert M.A., Vahdat, Olivier, Marcheix, Bertrand, Farah, Bruno, Serruys, Patrick W., Fajadet, Jean, Carrié, Didier, de Jaegere, Peter P.T., Colombo, Antonio, and Cardiology

Subjects
Edwards SAPIEN transcatheter, aortic valve implantation, Aortic stenosis, Medtronic CoreValve
Abstract

ObjectivesThe aim of this study was to compare outcomes after transfemoral transcatheter aortic valve implantation with the Medtronic CoreValve (MCV) versus the Edwards SAPIEN/SAPIEN XT transcatheter heart valve (ESV) for severe aortic stenosis.BackgroundNo large matched comparison study has been conducted so far evaluating both commercially available devices.MethodsThe data from databases of 4 experienced European centers were pooled and analyzed. Due to differences in baseline clinical characteristics, propensity score matching was performed. Study objectives were Valve Academic Research Consortium outcomes at 30 days and 1 year.ResultsIn total, 793 patients were included: 453 (57.1%) treated with the MCV and 340 (42.9%) with the ESV. After propensity matching, 204 patients were identified in each group. At 30 days, there were no differences in all-cause mortality (MCV, 8.8% vs. ESV, 6.4%; hazard ratio [HR]: 1.422; 95% confidence interval [CI]: 0.677 to 2.984; p = 0.352), cardiovascular mortality (MCV, 6.9% vs. ESV, 6.4%; HR: 1.083; 95% CI: 0.496 to 2.364; p = 0.842), myocardial infarction (MCV, 0.5% vs. ESV, 1.5%; HR: 0.330; 95% CI: 0.034 to 3.200; p = 0.339), stroke (MCV, 2.9% vs. ESV, 1.0%; HR: 3.061; 95% CI: 0.610 to 15.346; p = 0.174), or device success (MCV, 95.6% vs. ESV, 96.6%; HR: 0.770; 95% CI: 0.281 to 2.108; p = 0.611). Additionally, there were no differences in major vascular complications (MCV, 9.3% vs. ESV, 12.3%; HR: 0.735; 95% CI: 0.391 to 1.382; p = 0.340) or life-threatening bleeding (MCV, 13.7% vs. ESV, 8.8%; HR: 1.644; 95% CI: 0.878 to 3.077; p = 0.120). MCV was associated with more permanent pacemakers (22.5% vs. 5.9%; HR: 4.634; 95% CI: 2.373 to 9.050; p < 0.001). At 1 year, there were no differences in all-cause (MCV, 16.2% vs. ESV, 12.3%; HR: 1.374; 95% CI: 0.785 to 2.407; p = 0.266) or cardiovascular (MCV, 8.3% vs. ESV, 7.4%; HR: 1.145; 95% CI: 0.556 to 12.361; p = 0.713) mortality.ConclusionsNo differences between the 2 commercially available transfemoral transcatheter aortic valve implantation devices were observed at the adjusted analysis in Valve Academic Research Consortium outcomes except for the need for permanent pacemakers with the MCV.

Published
2013

23. Trends in the occurrence of new conduction abnormalities after transcatheter aortic valve implantation

Author

van der Boon, Robert M.A., primary, Houthuizen, Patrick, additional, Urena, Marina, additional, Poels, Thomas T., additional, van Mieghem, Nicolas M., additional, Brueren, Guus R.G., additional, Altintas, Sibel, additional, Nuis, Rutger Jan, additional, Serruys, Patrick W., additional, van Garsse, Leen A.F.M., additional, van Domburg, Ron T., additional, Cabau, Joseph Rodés, additional, de Jaegere, Peter P.T., additional, and Prinzen, Frits W., additional

Published
2014
Full Text
View/download PDF

25. Transcatheter aortic valve replacement and vascular complications definitions

Author

Van Mieghem, Nicolas M., primary, Généreux, Philippe, additional, van der Boon, Robert M.A., additional, Kodali, Susheel, additional, Head, Stuart, additional, Williams, Matthew, additional, Daneault, Benoit, additional, Kappetein, Arie-Pieter, additional, de Jaegere, Peter P., additional, Leon, Martin B., additional, and Serruys, Patrick W., additional

Published
2014
Full Text
View/download PDF

26. Transapical Versus Transfemoral Aortic Valve Implantation: A Multicenter Collaborative Study

Author

van der Boon, Robert M.A., primary, Marcheix, Bertrand, additional, Tchetche, Didier, additional, Chieffo, Alaide, additional, Van Mieghem, Nicolas M., additional, Dumonteil, Nicolas, additional, Vahdat, Olivier, additional, Maisano, Francesco, additional, Serruys, Patrick W., additional, Kappetein, A. Pieter, additional, Fajadet, Jean, additional, Colombo, Antonio, additional, Carrié, Didier, additional, van Domburg, Ron T., additional, and de Jaegere, Peter P.T., additional

Published
2014
Full Text
View/download PDF

28. Costs of Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients

Author

Osnabrugge, Ruben L.J., primary, Head, Stuart J., additional, Genders, Tessa S.S., additional, Van Mieghem, Nicolas M., additional, De Jaegere, Peter P.T., additional, van der Boon, Robert M.A., additional, Kerkvliet, J. Marco, additional, Kalesan, Bindu, additional, Bogers, Ad J.J.C., additional, Kappetein, A. Pieter, additional, and Hunink, M.G. Myriam, additional

Published
2012
Full Text
View/download PDF

30. TCT-89 Timing, Predictive Factors and Prognostic Value of Cerebrovascular Events in a Large Cohort of Patients Undergoing Transcatheter Aortic Valve Implantation

Author

Nombela-Franco, Luis, primary, Webb, John, additional, Jaegere, Peter De, additional, Toggweiler, Stefan, additional, Rutger, Jan Nuis, additional, Dager, Antonio, additional, Amat-Santos, Ignacio, additional, Cheung, Anson, additional, Ye, Jian, additional, Van Der Boon, Robert M.A., additional, Van Mieghem, Nicolas, additional, Benitez, Luis, additional, Binder, Ronald, additional, Perez, Sergio, additional, Lopez, Javier, additional, San Roman, Alberto, additional, Doyle, Daniel, additional, De Larochelliere, Robert, additional, Leipsic, Jonathon, additional, Dumont, Eric, additional, and Rodes-Cabau, Josep, additional

Published
2012
Full Text
View/download PDF

31. TCT-136 Impact of pre-operative chronic kidney disease on transcatheter aortic valve implantation outcome

Author

Dumonteil, Nicolas, primary, Chieffo, Alaide, additional, Tchetche, Didier, additional, Van Mieghem, Nicolas, additional, Marcheix, Bertrand, additional, Van Der Boon, Robert M.A., additional, Buchanan, Gill, additional, Vahdat, Olivier, additional, Serruys, Patrick, additional, Fajadet, Jean, additional, De Jaegere, Peter, additional, Colombo, Antonio, additional, and Carrié, Didier, additional

Published
2012
Full Text
View/download PDF

32. TCT-888 Patients With Aortic Stenosis Referred For Transcatheter Aortic Valve Implantation: Treatment Decision, In-hospital Outcome And Determinants Of Survival

Author

Nuis, Rutger-Jan, primary, Dager, Antonio, additional, Van Der Boon, Robert M.A., additional, Jaimes, Marisol, additional, Caicedo, Bernardo, additional, Fonseca, Jaimes, additional, van Mieghem, Nicolas, additional, Benitez, Luis, additional, Umana, Juan Pablo, additional, O'Neill, William, additional, de Marchena, Eduardo, additional, and De Jaegere, Peter, additional

Published
2012
Full Text
View/download PDF

33. TCT-884 Frequency And Causes Of Stroke During Or After Transcatheter Aortic Valve Implantation

Author

Nuis, Rutger-Jan, primary, Van Mieghem, Nicolas, additional, Schultz, Carl, additional, Moelker, Adriaan, additional, Van Der Boon, Robert M.A., additional, van Geuns, Robert-Jan, additional, van der Lugt, Aad, additional, Serruys, Patrick W., additional, Rodes-Cabau, Josep, additional, van Domburg, Ron, additional, Koudstaal, Peter, additional, and de Jaegere, Peter, additional

Published
2012
Full Text
View/download PDF

34. TCT-859 Transcatheter Aortic Valve Implantation with Edwards SAPIEN™ versus Medtronic CoreValve Revalving System® Devices: a Multi-Center Collaborative Study The PRAGMATIC Initiative – Pooled RotterdAm-Milano-Toulouse In Collaboration

Author

Chieffo, Alaide, primary, Buchanan, Gill, additional, Van Mieghem, Nicolas, additional, Latib, Azeem, additional, Tchetche, Didier, additional, Dumonteil, Nicolas, additional, Van der Boon, Robert M.A., additional, Vahdat, Olivier, additional, Marcheix, Bertrand, additional, Serruys, Patrick, additional, Carrié, Didier, additional, Fajadet, Jean, additional, De Jaegere, Peter, additional, Alfieri, Ottavio, additional, and Colombo, Antonio, additional

Published
2012
Full Text
View/download PDF

35. Left Bundle-Branch Block Induced by Transcatheter Aortic Valve Implantation Increases Risk of Death

Author

Houthuizen, Patrick, primary, Van Garsse, Leen A.F.M., additional, Poels, Thomas T., additional, de Jaegere, Peter, additional, van der Boon, Robert M.A., additional, Swinkels, Ben M., additional, ten Berg, Jurriën M., additional, van der Kley, Frank, additional, Schalij, Martin J., additional, Baan, Jan, additional, Cocchieri, Ricardo, additional, Brueren, Guus R.G., additional, van Straten, Albert H.M., additional, den Heijer, Peter, additional, Bentala, Mohamed, additional, van Ommen, Vincent, additional, Kluin, Jolanda, additional, Stella, Pieter R., additional, Prins, Martin H., additional, Maessen, Jos G., additional, and Prinzen, Frits W., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results